Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Tepotinib had robust, durable activity in TBx-positive/LBx-negative and TBx-positive/LBx-positive patients. Although LBx is a complementary method to TBx for detecting METex14, it may preferentially select patients with higher tumor burden and poorer prognosis. Undetectable METex14 in baseline ctDNA (due to low ctDNA shedding) may define more favorable treatment outcomes.
Authors
- Paul K. Paik (ORCID: https://orcid.org/0000-0002-9464-3984)
- Andreas Johne (ORCID: https://orcid.org/0000-0003-2690-2857)
- Christopher Stroh (ORCID: https://orcid.org/0009-0002-2635-4176)
- Aurora O’Brate
- Dilafruz Juraeva (ORCID: https://orcid.org/0000-0003-0035-3503)
- Rolf Bruns (ORCID: https://orcid.org/0000-0003-2305-3765)
- Christian Diego Rolfo (ORCID: https://orcid.org/0000-0002-7860-8417)
- Christoph Menzel
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Cornell University (US)
- Tisch Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4097
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- AstraZeneca
- Merck KGaA
- National Institutes of Health
- EMD Serono
- National Cancer Institute